Metformin Hexal

Metformin Hydrochloride, the active ingredient in Metformin Hexal, is a biguanide presented as a tablet for oral use. It lowers elevated blood glucose by reducing hepatic glucose production and enhancing peripheral insulin sensitivity, and is indicated for adults with type 2 diabetes mellitus.

All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release. The product is distributed through a secure cold‑chain logistics network to ensure integrity during transport. GNH USA supplies Metformin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Hexal acts on glucose metabolism pathways to improve glycemic control in type 2 diabetes mellitus.

Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c levels. Type 2 diabetes mellitus (adjunct therapy): enhances overall glycemic control when combined with other oral agents or insulin. Type 2 diabetes mellitus (initial monotherapy): can be used as first‑line oral treatment in newly diagnosed patients.

Metformin Hexal may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools, especially during dose titration. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: gradual decrease with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or angioedema. - Pancreatitis: inflammation of the pancreas. - Metabolic acidosis: non‑lactic acid accumulation.

Metformin Hexal requires careful patient assessment and monitoring.

Renal function assessment: evaluate eGFR before initiation and periodically thereafter. Hepatic impairment: avoid use in patients with significant liver disease. Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia or acidosis. Blood glucose monitoring: adjust dose based on fasting and post‑prandial glucose levels. Vitamin B12 monitoring: check levels during long‑term therapy. Pregnancy and lactation: weigh potential benefits against risks. Store at ambient temperature: keep in original container, protect from moisture.

Metformin Hexal can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Alcohol excess: heightens risk of lactic acidosis. - Carbonic anhydrase inhibitors (e.g., acetazolamide): may reduce renal clearance. - High‑dose vitamin B12 supplements: may mask deficiency.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt hypoglycemia symptoms. - Diuretics (thiazides): can raise blood glucose. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Sulfonylureas: increased risk of hypoglycemia. - Corticosteroids: may elevate glucose levels. - Thyroid hormones: adjust dose based on metabolic changes.